Drensteinfurt

Researchers are evaluating the safety and effectiveness of NT 201, a botulinum toxin drug, compared with a placebo in adults who have moderate to severe platysma prominence, which involves prominent neck bands. This Phase 3 study is conducted in Europe and focuses on improving the appearance of these neck muscles. The study aims to see how well NT 201 works and how safe it is for participants with this condition. Participants will receive either NT 201 or a matching placebo injection, which contains Clostridium Botulinum neurotoxin A without complexing proteins. The study has two parts: the Main Period (MP), where the initial treatment is given and evaluated, and an Open Label Extension Period (OLEX) that follows. The effectiveness is primarily measured by improvement on the Merz Aesthetics Platysma Scale - Dynamic (MAPS-D) at two weeks after treatment. During the study, participants will be assessed by both investigators and themselves for platysma band severity and improvement. Safety and treatment outcomes will be monitored throughout the study periods. The total involvement includes screening, treatment, and follow-up assessments to observe the drug's impact and any side effects over time.